每月彙整：四月 2019

《老謝看世界》2019.04.27 資本市場成了大國博弈舞台 謝金河 呂宗耀 繼續閱讀 →

Despite the number and proportion of women obtaining STEM degrees in the last few decades increasing considerably, representation in leadership positions in their respective fields has been fairly stagnant. According to the National Institutes of Health, “ Women comprise half of the employees in the pharmaceutical and medical industries, but available data suggest they represent about 17% of senior management positions. ” In fact, only 11% of board positions in biotechnology are filled by women, and just over 50% of biotechnology boards contain a woman at all. These numbers are even lower for minority women – highlighting a continuation of obstacles in the world of science for female leaders. 繼續閱讀 →

If you’ve been a Christian for any length of time, you’re familiar with the miraculous account of Christ’s resurrection. It brings hope for salvation, assurance for eternity, and comfort in times of grief or loss. But has it changed how you live? In this message, Dr. Stanley explains the impact Christ’s resurrection can have on your thinking, conversation, and conduct. His power over the grave can transform every aspect of your life. Learn more about the blessings that accompany our salvation. 繼續閱讀 →

【數字台灣】杜奕瑾聯手北醫 AI預測敗血症準確率達八成五！ 繼續閱讀 →

《老謝看世界》2019.04.20 自貿區捲土重來 勞退自選機制解救年輕人跳出勞保火坑 謝金河 馬凱 繼續閱讀 →

《文茜世界周報》巴黎人最心痛的一日　856年聖母院陷火海 繼續閱讀 →

彼得·德鲁克说，管理是一门真正的博雅艺术。然而，德鲁克心中的管理，可能与很多人所理解的大不相同。学习德鲁克，最重要的就是理解背后的原理。只有这样，才能不浪费你那些深藏心底的宝贵善意和与生俱来的创造力。 繼續閱讀 →

聖樂分享 繼續閱讀 →

Many believe behavior determines one’s eternal destination, and by being “good enough” they can earn their heavenly home. But they have not grasped the crucial nature of Christ’s death on the cross. Jesus came to end our frustrated and inadequate self-efforts, and offer us not only a better way, but the best. In this message, Dr. Stanley examines the full meaning of Christ’s sacrifice and all that it makes possible for those who believe. As we understand more about His substitutionary death on our behalf, our hearts will be filled with gratitude and the recognition of His abundant blessings. 繼續閱讀 →

Administration of a single broadly neutralizing human immunodeficiency virus (HIV)–specific antibody to HIV-infected persons leads to the development of antibody-resistant virus in the absence of antiretroviral therapy (ART). It is possible that monotherapy with UB-421, an antibody that blocks the virus-binding site on human CD4+ T cells, could induce sustained virologic suppression without induction of resistance in HIV-infected persons after analytic treatment interruption. 繼續閱讀 →

HIV treatment has come a long way since the early days of the epidemic. Patients can now take various combinations of dozens of medications keep the virus under control and halt their disease from decimating their immune systems and leading to more serious, often fatal outcomes.

But harnessing HIV requires daily vigilance. Missing doses of the pills can give the virus the chance to develop resistance to the drugs and lead to a surge in new copies of HIV that flood the body.

In a new study published in the New England Journal of Medicine, researchers at Taiwan-based United BioPharma report encouraging results with a single injection that seems to stymie HIV as well as daily pill regimens. The results add to a growing number of studies suggesting that patients may be able to take pill holidays without putting their health at risk. 繼續閱讀 →

Regular infusions of an antibody that blocks the HIV binding site on human immune cells may have suppressed levels of HIV for up to four months in people undergoing a short-term pause in their antiretroviral therapy (ART) regimens, according to a report published online today in The New England Journal of Medicine. Results of the Phase 2, open-label study indicate the antibody, known as UB-421, was safe and did not induce the production of antibody-resistant HIV. The study was supported in part by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health, and United Biopharma, Inc. 繼續閱讀 →

United BioPharma Announces Publication of Breakthrough HIV Clinical

Trial Data in the New England Journal of Medicine 繼續閱讀 →

聯合生物製藥(股)公司(聯生藥)今日宣布,其治療 HIV 感染之抗體新藥 UB-421
之臨床 II 期試驗結果以「Effect of Anti-CD4 Antibody UB-421 on HIV-1 Rebound
after Treatment Interruption」為題的原創論文,榮獲刊登於最新一期的新英格
蘭醫學期刊(The New England Journal of Medicine, NEJM)。 繼續閱讀 →

UB-421 Q & A 繼續閱讀 →